BR112022023049A2 - Proteínas multiespecíficas - Google Patents

Proteínas multiespecíficas

Info

Publication number
BR112022023049A2
BR112022023049A2 BR112022023049A BR112022023049A BR112022023049A2 BR 112022023049 A2 BR112022023049 A2 BR 112022023049A2 BR 112022023049 A BR112022023049 A BR 112022023049A BR 112022023049 A BR112022023049 A BR 112022023049A BR 112022023049 A2 BR112022023049 A2 BR 112022023049A2
Authority
BR
Brazil
Prior art keywords
proteins
nucleic acids
multiespecific
pharmaceutical compositions
multispecific
Prior art date
Application number
BR112022023049A
Other languages
English (en)
Inventor
Rigamonti Nicolo
Domke Clara
Perrine Calabro Valérie
Anna Trail Smith Pamela
Levitsky Victor
Elisabet Veitonmäki Niina
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BR112022023049A2 publication Critical patent/BR112022023049A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROTEÍNAS MULTIESPECÍFICAS. A presente invenção refere-se a proteínas multiespecíficas que compreendem domínios de repetição de anquirina projetados com especificidade de ligação para diferentes alvos, como, por exemplo, CD40 e FAP. Além disso, a invenção se refere a ácidos nucleicos que codificam tais proteínas multiespecíficas, a composições farmacêuticas que compreendem tais proteínas multiespecíficas ou ácidos nucleicos, e ao uso de tais proteínas de ligação, ácidos nucleicos ou composições farmacêuticas em métodos para tratar ou diagnosticar doenças, como o câncer, em um mamífero, incluindo um ser humano.
BR112022023049A 2020-05-14 2021-05-14 Proteínas multiespecíficas BR112022023049A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20174847 2020-05-14
EP20181498 2020-06-22
PCT/EP2021/062860 WO2021229067A1 (en) 2020-05-14 2021-05-14 Multispecific proteins

Publications (1)

Publication Number Publication Date
BR112022023049A2 true BR112022023049A2 (pt) 2022-12-20

Family

ID=75904957

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023049A BR112022023049A2 (pt) 2020-05-14 2021-05-14 Proteínas multiespecíficas

Country Status (13)

Country Link
US (1) US20210395318A1 (pt)
EP (1) EP4149959A1 (pt)
JP (1) JP2023528204A (pt)
KR (1) KR20230022176A (pt)
CN (1) CN115768786A (pt)
AU (1) AU2021271129A1 (pt)
BR (1) BR112022023049A2 (pt)
CA (1) CA3178785A1 (pt)
CO (1) CO2022017445A2 (pt)
IL (1) IL298168A (pt)
MX (1) MX2022014326A (pt)
TW (1) TW202208408A (pt)
WO (1) WO2021229067A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020399230A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Recombinant peptide-MHC complex binding proteins and their generation and use
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
MX2023010543A (es) 2021-03-09 2023-10-13 Molecular Partners Ag Ligadores multiespecificos de celulas t novedosos basados en darpin.
WO2023110983A1 (en) * 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP2010539915A (ja) 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
JP5954990B2 (ja) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
EP2483316A1 (en) 2009-10-02 2012-08-08 Ludwig Institute for Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818990C (en) 2010-11-26 2021-06-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
BR112014032316A2 (pt) 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
ES2953482T3 (es) 2015-04-02 2023-11-13 Molecular Partners Ag Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
MX2019003298A (es) 2016-09-22 2019-09-26 Molecular Partners Ag Proteinas de union recombinantes y sus usos.
CA3053358A1 (en) * 2017-04-04 2018-10-11 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
KR20210069675A (ko) * 2018-10-01 2021-06-11 에프. 호프만-라 로슈 아게 항-fap 클론 212를 포함하는 이중특이적 항원 결합 분자

Also Published As

Publication number Publication date
EP4149959A1 (en) 2023-03-22
US20210395318A1 (en) 2021-12-23
JP2023528204A (ja) 2023-07-04
TW202208408A (zh) 2022-03-01
CA3178785A1 (en) 2021-11-18
CN115768786A (zh) 2023-03-07
MX2022014326A (es) 2023-02-09
CO2022017445A2 (es) 2023-02-16
AU2021271129A1 (en) 2022-12-15
WO2021229067A1 (en) 2021-11-18
AU2021271129A9 (en) 2023-03-02
IL298168A (en) 2023-01-01
KR20230022176A (ko) 2023-02-14

Similar Documents

Publication Publication Date Title
BR112022023049A2 (pt) Proteínas multiespecíficas
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112019000598A2 (pt) rna para terapia de câncer
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
BR112021024231A2 (pt) Proteínas de ligação fap recombinantes e uso da mesma
BR112022022456A2 (pt) Proteínas de ligação de repetição de anquirina e seus usos
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
BR112012027765A2 (pt) métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BRPI0809594A2 (pt) polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BRPI0622054B8 (pt) composto e composição farmacêutica
BR112017017530A2 (pt) proteínas específicas para pioverdina e pioquelina
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
BR112017017825A2 (pt) semaforinas 3 não naturais e seu uso médico
MX2022007120A (es) Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.
BRPI0800585B8 (pt) composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
BRPI0912475B8 (pt) compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112022011854A2 (pt) Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
BR112021008774A2 (pt) Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer